What is Claimed is:

1. A pharmaceutical composition comprising, at least one of mammalian mesenchymal stem cells (MSCs) and mesenchymal stem cells derived from induced pluripotent stem cells (iMSCs) that have been exposed to one or more activating agents *in vitro* or *ex vivo* comprising one or more Toll-like receptor 3 (TLR3) agonist selected from the group consisting of polyadenylic-polyuridylic acid (poly(A:U), polyinosine-polycytidylic acid (pIC), and UV-inactivated viral particles, wherein the activated mesenchymal stem cells are immunostimulatory and are capable of treating an infected wound or infected tissue in a subject; and one or more pharmaceutically acceptable carriers, diluents, or excipients.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for intravenous administration.

3. The pharmaceutical composition of claim 2, wherein the MSCs or iMSCs are obtained or derived from bone marrow, adipose tissue, blood, cord blood, umbilical cord tissue, placenta, tissue biopsies, dental biopsies, or skin.

4. The pharmaceutical composition of claim 1, wherein iMSCs are generated from differentiated induced pluripotent stem cells and wherein the induced pluripotent stem cells comprise induced pluripotent stem cells generated from adult tissues.

5. The pharmaceutical composition of claim 1, wherein the MSCs or iMSCs are activated by *in vitro* incubation with the one or more activating agents.

6. The pharmaceutical composition of claim 1, wherein the one or more activating agents comprises, polyinosine-polycytidylic acid (pIC).

7. The pharmaceutical composition of claim 1, wherein the one or more activating agents comprises pIC and wherein the concentration is about 10 μg/ml.

8. The pharmaceutical composition of claim 1, wherein the composition further comprises one or more antimicrobial agents, and optionally, wherein the one or more antimicrobial agents is a bactericidal antibiotic or a bacteriostatic antibiotic.

9. The pharmaceutical composition of claim 8, wherein the bactericidal antibiotic is selected from the group consisting of penicillin derivatives (penams), cephalosporins (cephams), monobactams, carbapenems, vancomycin, daptomycin, fluoroquinolones, metronidazole, nitrofurantoin, co-trimoxazole, telithromycin, and aminoglycosidic antibiotics.

10. The pharmaceutical composition of claim 8, wherein the bacteriostatic antibiotic is selected from the group consisting of tetracycline antibiotics, choloramphenicol, erythromycin, clindamycin, and linezolid, and wherein the tetracycline antibiotic is selected from the group consisting of tetracycline, doxycycline, and minocycline.

11. The pharmaceutical composition of claim 1, wherein the MSCs are human MSCs.

12. The pharmaceutical composition of claim 1, wherein the one or more activating agent is polyinosinic:polycytidylic acid (pIC); optionally, wherein the pIC is synthetic.

13. The pharmaceutical composition of claim 1, wherein activated MSCs enrich monocyte recruitment to the wound site and; wherein the recruited monocytes at the wound site differentiate into macrophages comprising M1 and M2 macrophages.

14. Use of the pharmaceutical composition of any one of claims 1-12, in the manufacture of a medicament for treating a non-healing infected wound or chronically-infected tissue or chronically-infected wound in a mammal, wherein the pharmaceutical composition comprising the activated MSCs treat the non-healing or chronically-infected tissue or chronically-infected wound.

15. The use of claim 14, wherein the medicament is formulated for intravenous administration.

16. The use of claim 14, wherein the non-healing or chronically-infected tissue or chronically-infected wound comprises one or more of abrasions, deep-seated or inaccessible wound, lacerations, contusions, concussions, stab wounds, skin cuts, surgical wounds, gunshot wounds, or other trauma causing an infected tissue, burns, sunburns, diabetic ulcers, frostbite,

chemical wounds, insect bites, animal bites, insect, stings and electrical wounds.

17. The use of claim 14, wherein the activated MSC composition is to be administered along with or separately from, one or more antibacterial agents or bacteriostatic agent or antibiotic.

18. The use of claim 14, wherein the activated MSC composition does not contain an antimicrobial agent and the pharmaceutical composition is to be administered to a subject having a chronically infected wound already undergoing a treatment regimen comprising an antimicrobial agent.

19. The use of claim 14, wherein the non-healing or chronically-infected tissue or chronically-infected wound comprises at least one of a non-healing or chronically-infected tissue or chronically-infected wound harboring more than one pathogenic microorganism and a non-healing or a chronically-infected tissue or chronically-infected wound infected with at least one drug resistant microorganism.

20. The use of claim 14, wherein the pharmaceutical composition is to be administered intravenously to the mammal daily, bi-weekly, weekly, every 10 days, every 2 weeks, or once a month for about 1 to about 10 doses; and wherein an antimicrobial agent is to be administered before during or after each activated MSC or activated iMSC pharmaceutical composition dose.

21. The use of any one of claims 14-20, wherein the pharmaceutical composition further comprises an antimicrobial agent selected from the group consisting of one or more cephlasporins, penicillins, quinolones, tetracyclines, metronidazole, aminoglycosides or combinations thereof.

22. A kit comprising the pharmaceutical composition of any one of claims 1-13; and at least one container.